{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:40:00Z","timestamp":1794559200809,"version":"4.9.1"},"reference-count":135,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.revmed.2024.10.452","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:02:35Z","timestamp":1731686555000},"page":"89-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases"],"prefix":"10.1016","volume":"46","author":[{"given":"Liticia","family":"Chikhoune","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6454-5851","authenticated-orcid":false,"given":"Claire","family":"Poggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Dubucquoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8279-1912","authenticated-orcid":false,"given":"Aurore","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1840-1817","authenticated-orcid":false,"given":"David","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.revmed.2024.10.452_bib0680","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J Cell Sci"},{"issue":"4","key":"10.1016\/j.revmed.2024.10.452_bib0685","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaci.2021.08.004","article-title":"JAK-STAT signaling in human disease: from genetic syndromes to clinical inhibition","volume":"148","author":"Luo","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.revmed.2024.10.452_bib0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.revmed.2024.10.452_bib0695","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.3389\/fimmu.2018.02392","article-title":"Protein inhibitor of activated STAT (PIAS) negatively regulates the JAK\/STAT pathway by inhibiting STAT phosphorylation and translocation","volume":"9","author":"Niu","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.revmed.2024.10.452_bib0700","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ni.1701","article-title":"Selectivity and therapeutic inhibition of kinases: to be or not to be?","volume":"10","author":"Ghoreschi","year":"2009","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.revmed.2024.10.452_bib0705","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.revmed.2024.10.452_bib0710","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"10.1016\/j.revmed.2024.10.452_bib0715","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","article-title":"The JAK-STAT signaling pathway: input and output integration","volume":"178","author":"Murray","year":"2007","journal-title":"J Immunol"},{"issue":"Suppl. 1","key":"10.1016\/j.revmed.2024.10.452_bib0720","doi-asserted-by":"crossref","first-page":"100","DOI":"10.31138\/mjr.31.1.100","article-title":"Basic mechanisms of JAK inhibition","volume":"31","author":"Lin","year":"2020","journal-title":"Mediterr J Rheumatol"},{"issue":"5","key":"10.1016\/j.revmed.2024.10.452_bib0725","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.revmed.2024.10.452_bib0730","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"10.1016\/j.revmed.2024.10.452_bib0735","doi-asserted-by":"crossref","first-page":"e000308","DOI":"10.1136\/rmdopen-2016-000308","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial","volume":"2","author":"Strand","year":"2016","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.revmed.2024.10.452_bib0740","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.revmed.2024.10.452_bib0745","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four\u2013month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"25","key":"10.1016\/j.revmed.2024.10.452_bib0750","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.revmed.2024.10.452_bib0755","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1136\/annrheumdis-2017-211259","article-title":"Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study","volume":"76","author":"Keystone","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.revmed.2024.10.452_bib0760","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/rheumatology\/keaa576","article-title":"Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study","volume":"60","author":"Smolen","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"10139","key":"10.1016\/j.revmed.2024.10.452_bib0765","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"issue":"10139","key":"10.1016\/j.revmed.2024.10.452_bib0770","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.revmed.2024.10.452_bib0775","doi-asserted-by":"crossref","first-page":"5583","DOI":"10.1093\/rheumatology\/keab158","article-title":"Upadacitinib improves patient-reported outcomes vs. placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE","volume":"60","author":"Strand","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.revmed.2024.10.452_bib0780","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator\u2013controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.revmed.2024.10.452_bib0785","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs. placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.revmed.2024.10.452_bib0790","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.revmed.2024.10.452_bib0795","doi-asserted-by":"crossref","first-page":"e000808","DOI":"10.1136\/rmdopen-2018-000808","article-title":"Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"issue":"10188","key":"10.1016\/j.revmed.2024.10.452_bib0800","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.revmed.2024.10.452_bib0805","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/rheumatology\/kez408","article-title":"Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)","volume":"59","author":"Orbai","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.revmed.2024.10.452_bib0810","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"10214","key":"10.1016\/j.revmed.2024.10.452_bib0815","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"issue":"10162","key":"10.1016\/j.revmed.2024.10.452_bib0820","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.revmed.2024.10.452_bib0825","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cgh.2021.02.043","article-title":"Efficacy and safety of tofacitinib in ulcerative colitis based on prior tumor necrosis factor inhibitor failure status","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl. 2","key":"10.1016\/j.revmed.2024.10.452_bib0830","doi-asserted-by":"crossref","first-page":"S746","DOI":"10.1093\/ecco-jcc\/jjz186","article-title":"Efficacy of JAK inhibitors in Crohn's disease","volume":"14","author":"Rogler","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"8","key":"10.1016\/j.revmed.2024.10.452_bib0835","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"10066","key":"10.1016\/j.revmed.2024.10.452_bib0840","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.revmed.2024.10.452_bib0845","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treat-ment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.revmed.2024.10.452_bib0850","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2024.10.452_bib0855","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2024.10.452_bib0860","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","article-title":"Delgocitinib oint-ment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"82","author":"Nakagawa","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.revmed.2024.10.452_bib0865","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2024.10.452_bib0870","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2024.10.452_bib0875","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2024.10.452_bib0880","unstructured":"Bristol Myers Squibb presents positive data from two pivotal phase 3 psoriasis studies demonstrating superiority of deu-cravacitinib compared to placebo and otezla\u00ae (apremilast). [Available from: https:\/\/news.bms.com\/news\/details\/2021\/Bris-tol-Myers-Squibb-Presents-Positive-Data-from-Two-Pivotal-Phase-3-Psoriasis-Studies-Demonstrating-Superiority-of-Deu-cravacitinib-Compared-to-Placebo-and-Otezla-apremilast\/default.aspx (Last accessed July 17, 2021)]."},{"key":"10.1016\/j.revmed.2024.10.452_bib0885","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13555-019-00347-w","article-title":"Systemic treatment of psoriasis with JAK inhibitors: a review","volume":"10","author":"Kvist-Hansen","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.revmed.2024.10.452_bib0890","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"33","author":"Phan","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.revmed.2024.10.452_bib0895","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/art.39818","article-title":"Tofacitinib ameliorates murine lupus and its associated vascular dysfunction","volume":"69","author":"Furumoto","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.revmed.2024.10.452_bib0900","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/0961203306075383","article-title":"Activation of the STAT1 signalling pathway in lupus nephritis in MRL\/lpr mice","volume":"16","author":"Dong","year":"2007","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.revmed.2024.10.452_bib0905","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0961203310367660","article-title":"Jak\/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL\/lpr mice","volume":"19","author":"Wang","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2024.10.452_bib0910","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13075-016-1034-x","article-title":"JAK3-STAT pathway blocking benefits in experimental lupus nephritis","volume":"18","author":"Ripoll","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.revmed.2024.10.452_bib0915","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/jid.2015.107","article-title":"Ruxolitinib attenuates cutaneous lupus development in a mouse lupus model","volume":"135","author":"Chan","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"18","key":"10.1016\/j.revmed.2024.10.452_bib0920","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1093\/hmg\/ddn184","article-title":"A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5","volume":"17","author":"Sigurdsson","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.revmed.2024.10.452_bib0925","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.revmed.2024.10.452_bib0930","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/annrheumdis-2019-215455","article-title":"Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre","volume":"78","author":"You","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10143","key":"10.1016\/j.revmed.2024.10.452_bib0935","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"issue":"10170","key":"10.1016\/j.revmed.2024.10.452_bib0940","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0140-6736(18)32763-6","article-title":"Baricitinib for systemic lupus erythematosus","volume":"393","author":"Yuan","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.revmed.2024.10.452_bib0945","first-page":"460","article-title":"FDA approves Eli Lilly's baricitinib","volume":"17","author":"Mullard","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.revmed.2024.10.452_bib0950","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13075-022-02794-x","article-title":"Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial","volume":"24","author":"D\u00f6rner","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"10381","key":"10.1016\/j.revmed.2024.10.452_bib0955","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet"},{"issue":"10381","key":"10.1016\/j.revmed.2024.10.452_bib0960","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.revmed.2024.10.452_bib0965","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/jid.2015.107","article-title":"Ruxolitinib Attenuates cutaneous lupus development in a mouse lupus model","volume":"135","author":"Chan","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.revmed.2024.10.452_bib0970","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jid.2016.02.015","article-title":"JAK1\/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus","volume":"136","author":"Wenzel","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.revmed.2024.10.452_bib0975","doi-asserted-by":"crossref","first-page":"e001490","DOI":"10.1136\/rmdopen-2020-001490","article-title":"Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy","volume":"6","author":"Baker","year":"2020","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.revmed.2024.10.452_bib0980","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/rheumatology\/keab685","article-title":"Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study","volume":"61","author":"Werth","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"502","key":"10.1016\/j.revmed.2024.10.452_bib0985","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Translational Med"},{"issue":"2","key":"10.1016\/j.revmed.2024.10.452_bib0990","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.revmed.2024.10.452_bib0995","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/cei.12194","article-title":"Diagnosis, pathogenesis and treatment of myositis: recent advances","volume":"175","author":"Carstens","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.revmed.2024.10.452_bib1000","doi-asserted-by":"crossref","first-page":"e14939","DOI":"10.1111\/dth.14939","article-title":"JAK-inhibitors for dermatomyositis: a concise literature review","volume":"34","author":"Paudyal","year":"2021","journal-title":"Dermatol Ther"},{"issue":"11","key":"10.1016\/j.revmed.2024.10.452_bib1005","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1093\/rheumatology\/keab421","article-title":"Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series","volume":"60","author":"Shneyderman","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2024.10.452_bib1010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","article-title":"Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib\u00a0\u2013\u00a0A report of two cases","volume":"100","author":"Wendel","year":"2019","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.revmed.2024.10.452_bib1015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40674-021-00186-x","article-title":"Pharmacologic treatment of anti-MDA5 rapidly progressive interstitial lung disease","volume":"7","author":"Selva-O\u2019Callaghan","year":"2021","journal-title":"Curr Treatm Opt Rheumatol"},{"issue":"12","key":"10.1016\/j.revmed.2024.10.452_bib1020","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology"},{"issue":"8S","key":"10.1016\/j.revmed.2024.10.452_bib1025","doi-asserted-by":"crossref","first-page":"S574","DOI":"10.1097\/RHU.0000000000000984","article-title":"Successful treatment for refractory interstitial lung disease and pneumomediastinum with multidisciplinary therapy including tofacitinib in a patient with anti-MDA5 Antibody-positive dermatomyositis","volume":"27","author":"Kato","year":"2021","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.revmed.2024.10.452_bib1030","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis\u2013associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2024.10.452_bib1035","doi-asserted-by":"crossref","first-page":"108451","DOI":"10.1016\/j.clim.2020.108451","article-title":"Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis","volume":"215","author":"Takatani","year":"2020","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.revmed.2024.10.452_bib1040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/24725625.2020.1816674","article-title":"Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies","volume":"5","author":"Ohmura","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"issue":"8","key":"10.1016\/j.revmed.2024.10.452_bib1045","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1016\/j.transproceed.2021.08.012","article-title":"High-emergency lung transplantation for interstitial lung disease associated with anti-MDA5 dermatomyositis: a case report","volume":"53","author":"Marchiset","year":"2021","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.revmed.2024.10.452_bib1050","first-page":"291","article-title":"Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis","volume":"41","author":"Shirai","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.revmed.2024.10.452_bib1055","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of Tofacitinib In Refractory Dermatomyositis (STIR): an open label pilot study of 10 patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.revmed.2024.10.452_bib1060","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jaad.2022.08.025","article-title":"Baricitinib for the treatment of cutaneous dermatomyositis: a prospective, open-label study","volume":"87","author":"Zhao","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.revmed.2024.10.452_bib1065","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1093\/rheumatology\/keaa377","article-title":"Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis","volume":"59","author":"Delvino","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.revmed.2024.10.452_bib1070","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1093\/brain\/awy256","article-title":"Reply: a child with severe juvenile dermatomyositis treated with ruxolitinib","volume":"141","author":"Allenbach","year":"2018","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.revmed.2024.10.452_bib1075","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1093\/brain\/awy255","article-title":"A child with severe juvenile dermatomyositis treated with ruxolitinib","volume":"141","author":"Aeschlimann","year":"2018","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.revmed.2024.10.452_bib1080","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1093\/rheumatology\/keaa657","article-title":"Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis?","volume":"60","author":"Heinen","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"26","key":"10.1016\/j.revmed.2024.10.452_bib1085","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1056\/NEJMc1412997","article-title":"Remission of recalcitrant dermatomyositis treated with ruxolitinib","volume":"371","author":"Hornung","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.revmed.2024.10.452_bib1090","first-page":"348","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.revmed.2024.10.452_bib1095","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.revmed.2024.10.452_bib1100","doi-asserted-by":"crossref","first-page":"109723","DOI":"10.1016\/j.intimp.2023.109723","article-title":"Effects of ruxolitinib on fibrosis in preclinical models of systemic sclerosis","volume":"116","author":"Bellamri","year":"2023","journal-title":"Intern Immunopharmacol"},{"issue":"3","key":"10.1016\/j.revmed.2024.10.452_bib1105","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jdermsci.2020.12.007","article-title":"Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma","volume":"101","author":"Aung","year":"2021","journal-title":"J Dermatol Sci"},{"issue":"10","key":"10.1016\/j.revmed.2024.10.452_bib1110","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1074\/jbc.M116.773085","article-title":"Transforming growth factor-\u03b2 (TGF-\u03b2) directly activates the JAK1-STAT3 axis to induce hepatic fibrosis in coordination with the SMAD pathway","volume":"292","author":"Tang","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.revmed.2024.10.452_bib1115","doi-asserted-by":"crossref","first-page":"154635","DOI":"10.1016\/j.cyto.2018.12.018","article-title":"Type I interferon dysregulation in systemic sclerosis","volume":"132","author":"Skaug","year":"2020","journal-title":"Cytokine"},{"issue":"8","key":"10.1016\/j.revmed.2024.10.452_bib1120","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","volume":"75","author":"Brkic","year":"2016","journal-title":"Ann Rheumatic Dis"},{"issue":"6","key":"10.1016\/j.revmed.2024.10.452_bib1125","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3899\/jrheum.111423","article-title":"Interleukin 6 in systemic sclerosis and potential implications for targeted therapy","volume":"39","author":"Muangchan","year":"2012","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.revmed.2024.10.452_bib1130","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","article-title":"Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis","volume":"77","author":"Denton","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.revmed.2024.10.452_bib1135","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.revmed.2024.10.452_bib1140","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/2397198319865367","article-title":"The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib","volume":"5","author":"Wang","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"issue":"10","key":"10.1016\/j.revmed.2024.10.452_bib1145","doi-asserted-by":"crossref","first-page":"103168","DOI":"10.1016\/j.autrev.2022.103168","article-title":"JAK inhibitors and systemic sclerosis: a systematic review of the literature","volume":"21","author":"Moriana","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.revmed.2024.10.452_bib1150","first-page":"2008","article-title":"Improvement of salt and pepper skin changes in diffuse scleroderma after treatment with tofacitinib","volume":"40","author":"Nallapati","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.revmed.2024.10.452_bib1155","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1111\/jdv.14876","article-title":"The use of JAK inhibitors in the treatment of progressive systemic sclerosis","volume":"32","author":"Deverapalli","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.revmed.2024.10.452_bib1160","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1093\/rheumatology\/keaa613","article-title":"Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis","volume":"60","author":"You","year":"2021","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.revmed.2024.10.452_bib1165","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00296-021-04956-7","article-title":"Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound","volume":"41","author":"Karalilova","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.revmed.2024.10.452_bib1170","doi-asserted-by":"crossref","first-page":"1125836","DOI":"10.3389\/fmed.2022.1125836","article-title":"Corrigendum: JAK1\/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis","volume":"9","author":"Hou","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"10.1016\/j.revmed.2024.10.452_bib1175","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.3390\/life12122101","article-title":"Potential role of JAK inhibitors in the treatment of systemic sclerosis-associated interstitial lung disease: a narrative review from pathogenesis to real-life data","volume":"12","author":"Fiorentini","year":"2022","journal-title":"Life"},{"issue":"3","key":"10.1016\/j.revmed.2024.10.452_bib1180","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7150\/ijms.17718","article-title":"Reviewing primary Sj\u00f6gren's syndrome: beyond the dryness\u00a0\u2013\u00a0From pathophysiology to diagnosis and treatment","volume":"14","author":"Both","year":"2017","journal-title":"Int J Med Sci"},{"issue":"6","key":"10.1016\/j.revmed.2024.10.452_bib1185","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/art.40040","article-title":"Genome-Wide association analysis reveals genetic heterogeneity of Sj\u00f6gren's syndrome according to ancestry","volume":"69","author":"Taylor","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.revmed.2024.10.452_bib1190","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clim.2017.04.018","article-title":"Genetics of Sj\u00f6gren's syndrome","volume":"182","author":"Teos","year":"2017","journal-title":"Clin Immunol"},{"issue":"12","key":"10.1016\/j.revmed.2024.10.452_bib1195","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.revmed.2019.07.016","article-title":"Les inhibiteurs de JAK\u00a0: perspectives pour la m\u00e9decine interne","volume":"40","author":"El Jammal","year":"2019","journal-title":"Rev Med Interne"},{"issue":"1","key":"10.1016\/j.revmed.2024.10.452_bib1200","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s10753-020-01322-w","article-title":"Inhibition of JAK-STAT signaling by baricitinib reduces interferon-\u03b3-induced CXCL10 production in human salivary gland ductal cells","volume":"44","author":"Aota","year":"2021","journal-title":"Inflammation"},{"issue":"7","key":"10.1016\/j.revmed.2024.10.452_bib1205","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/annrheumdis-2021-222053","article-title":"Pilot study of baricitinib for active Sjogren's syndrome","volume":"81","author":"Bai","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.revmed.2024.10.452_bib1210","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","article-title":"Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sj\u00f6gren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study","volume":"61","author":"Price","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.revmed.2024.10.452_bib1215","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1038\/s41598-017-04109-6","article-title":"Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"issue":"26","key":"10.1016\/j.revmed.2024.10.452_bib1220","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.revmed.2024.10.452_bib1225","doi-asserted-by":"crossref","first-page":"1801482","DOI":"10.1183\/13993003.01482-2018","article-title":"Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia","volume":"52","author":"Rotenberg","year":"2018","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.revmed.2024.10.452_bib1230","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jdcr.2019.02.006","article-title":"Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera","volume":"5","author":"Wei","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"11","key":"10.1016\/j.revmed.2024.10.452_bib1235","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1136\/annrheumdis-2019-215387","article-title":"Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib","volume":"78","author":"Levraut","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.revmed.2024.10.452_bib1240","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/art.1780270113","article-title":"Cytokine modulation of chondrocyte proteinase release","volume":"27","author":"Herman","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"6079","key":"10.1016\/j.revmed.2024.10.452_bib1245","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/322547a0","article-title":"Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage","volume":"322","author":"Saklatvala","year":"1986","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.revmed.2024.10.452_bib1250","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/14712598.2022.2048647","article-title":"Biologic therapy in relapsing polychondritis: navigating between options","volume":"22","author":"Padoan","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"10.1016\/j.revmed.2024.10.452_bib1255","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1136\/annrheumdis-2018-213554","article-title":"Tofacitinib in steroid-dependent relapsing polychondritis","volume":"78","author":"Meshkov","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.revmed.2024.10.452_bib1260","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40123-019-0171-0","article-title":"Reviewing the pathophysiology behind the advances in the management of giant cell arteritis","volume":"8","author":"Al-Mousawi","year":"2019","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"10.1016\/j.revmed.2024.10.452_bib1265","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/RLU.0000000000003913","article-title":"JAK Inhibitor effectiveness in giant-cell arteritis with large-vessel involvement assessed by 18F-FDG PET-CT","volume":"47","author":"Prigent","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1016\/j.revmed.2024.10.452_bib1270","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1056\/NEJMra022694","article-title":"Medium- and large-vessel vasculitis","volume":"349","author":"Weyand","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.revmed.2024.10.452_bib1275","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1172\/JCI117029","article-title":"Perforin-secreting killer cell infiltration and expression of a 65-kD heat-shock protein in aortic tissue of patients with Takayasu's arteritis","volume":"93","author":"Seko","year":"1994","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.revmed.2024.10.452_bib1280","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/annrheumdis-2021-220832","article-title":"Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study","volume":"81","author":"Kong","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.revmed.2024.10.452_bib1285","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/sji.12211","article-title":"Differential expression of suppressor of cytokine signalling proteins in Beh\u00e7et's disease","volume":"80","author":"Hamedi","year":"2014","journal-title":"Scand J Immunol"},{"issue":"11","key":"10.1016\/j.revmed.2024.10.452_bib1290","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/annrheumdis-2020-217307","article-title":"A pilot study of tofacitinib for refractory Beh\u00e7et's syndrome","volume":"79","author":"Liu","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.revmed.2024.10.452_bib1295","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/annrheumdis-2021-220484","article-title":"Tofacitinib for the treatment of antineutrophil cytoplasm antibody-associated vasculitis: a pilot study","volume":"80","author":"Liu","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.revmed.2024.10.452_bib1300","doi-asserted-by":"crossref","first-page":"e2055","DOI":"10.1136\/annrheumdis-2020-218790","article-title":"Response to: \u2018Tofacitinib for the treatment of polyarteritis nodosa: a literature review\u2019. Correspondence on \u2018Tofacitinib for polyarteritis nodosa: a tailored therapy\u2019 by Rimar et al","volume":"81","author":"Rimar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2024.10.452_bib1305","doi-asserted-by":"crossref","first-page":"695768","DOI":"10.3389\/fimmu.2021.695768","article-title":"Tofacitinib treatment of refractory cutaneous leukocytoclastic vasculitis: a case report","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Immunol"},{"issue":"10315","key":"10.1016\/j.revmed.2024.10.452_bib1310","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.revmed.2024.10.452_bib1315","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1182\/blood.2020010177","article-title":"Therapeutic options in VEXAS syndrome: insights from a retrospective series","volume":"137","author":"Bourbon","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2024.10.452_bib1320","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221093211","article-title":"Clinical and immunological study of tofacitinib and baricitinib in refractory Blau syndrome: case report and literature review","volume":"14","author":"\u00c1lvarez-Reguera","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"10.1016\/j.revmed.2024.10.452_bib1325","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2016-02-700013","article-title":"Therapeutic effect of JAK1\/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice","volume":"128","author":"Maschalidi","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.revmed.2024.10.452_bib1330","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/rheumatology\/key006","article-title":"Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment","volume":"58","author":"Carter","year":"2019","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.revmed.2024.10.452_bib1335","first-page":"1376","article-title":"[Establishment of secondary HLH mouse model and effect of ruxolitinib on disease manifestations of model Mide]","volume":"28","author":"Meng","year":"2020","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"12","key":"10.1016\/j.revmed.2024.10.452_bib1340","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial","volume":"6","author":"Ahmed","year":"2019","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.revmed.2024.10.452_bib1345","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.3324\/haematol.2019.222471","article-title":"Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.revmed.2024.10.452_bib1350","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjh.17331","article-title":"Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory\/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial","volume":"193","author":"Wang","year":"2021","journal-title":"Br J Haematol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866324012517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866324012517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T06:14:06Z","timestamp":1739340846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866324012517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":135,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0248866324012517"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2024.10.452","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2024.10.452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}